PHARMANOVIA
PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ONLY
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918003077/en/
James Burt, CEO, Pharmanovia (Photo: Business Wire)
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi.
The brands span four therapy areas of ongoing unmet need associated with CNS disorders - psycholeptic, anxiolytic, anti-epileptic and anti-psychotic.
Clobazam is from a class of drug called benzodiazepines and can be used to treat anxiety, with or without insomnia or certain psychiatric conditions, in certain patients.1 The acquired brands include Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren® and Castilium®*. Frisium® may also be used as adjunctive therapy in epilepsy.1
Phenobarbital (brand: Gardenal®*) is used as an anti-convulsant to treat all forms of epilepsy except absence seizures.2
Cyamemazine (brand: Tercian®*†) is used to treat certain types of psychotic conditions, anxiety in patients where other treatments have failed and also some types of depression in combination with another anti-depressant.3
Prochlorperazine (brand: Stemetil®*) is used to treat vertigo, and nausea and vomiting due to various causes. It may also be used for other conditions such as schizophrenia, acute mania and as an adjunct to the short-term management of anxiety.4,5
Dr James Burt, Pharmanovia CEO, commented: “Sanofi’s decision to divest this established CNS portfolio, with leading brands such as Frisium® and Gardenal®, to Pharmanovia is recognition of our neurology expertise, our capabilities in lifecycle management and reputation of being a trusted divestment partner. We’re excited to use this knowledge and our global platform to ensure these important medicines not only continue to be available to the millions of patients who need them, but - through our lifecycle management - continue to evolve to meet patient needs.”
“Through this acquisition, we are not only building depth in geography, but we’re also bringing in products that have a clear synergy with our existing portfolio and the core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need.”
-Ends-
Notes to editors
*Not all indications are approved in every market. For local indications it is advised to check the local approved label. †Tercian® is only available in France.
About Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by enhancing established medicines by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and strategic partnerships.
Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
For more information about Pharmanovia, please visit www.pharmanovia.com
About Sanofi
Sanofi is an innovative global healthcare company, driven by one purpose: to chase the miracles of science to improve people’s lives. Its team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of its ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
References
1 - Frisium Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/1574 – last accessed 11.9.2023
2 - Phenobarbital Sodium Injection Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/3604/smpc#gref - last accessed 11.9.2023
3 - Terican Summary of Product Characteristics, https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66615713&typedoc=R – last accessed 11.9.2023
4 - Stemetil Injection Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/3735/smpc#about-medicine - last accessed 11.9.2023
5 - Stemetil Tablets Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/99/smpc#about-medicine - last accessed 11.9.2023
COR2023PR00207 – Date of Preparation – 14.9.2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918003077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DE-INCYTE29.9.2023 19:44:31 CEST | Press release
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
CA-ANDERSEN-GLOBAL29.9.2023 17:25:34 CEST | Pressemeddelelse
Andersen lancerer global værdiansættelsespraksis
Q429.9.2023 17:13:42 CEST | Press release
Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail
CA-GEDI-CUBE29.9.2023 15:49:11 CEST | Press release
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine
ALLIANZ-SE29.9.2023 13:54:35 CEST | Press release
Offshore Windfarm Hollandse Kust Zuid Inaugurated
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom